Nephros claims US first for haemodiafiltration
This article was originally published in Clinica
Signalling the company's entry into the US renal care market, New York-based Nephros has received FDA 510(k) clearance to market its OLpur HD190 high flux filter for use in treatments for kidney failure.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.